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The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the 
hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), 
respectively. This shifts the pro-inflammatory milieu induced by extracellular ATP to 
the anti-inflammatory regulation by Ado. Mesenchymal stem cells (MSCs) have potent 
immunomodulatory capabilities, including monocyte modulation toward an anti-in-
flammatory phenotype aiding tissue repair. In vitro, we observed that human cardiac 
adipose tissue-derived MSCs (cATMSCs) and umbilical cord MSCs similarly polarize 
monocytes toward a regulatory M2 phenotype, which maintained the expression of 
CD39 and induced expression of CD73 in a cell contact dependent fashion, correlating 
with increased functional activity. In addition, the local treatment with porcine cATMSCs 
using an engineered bioactive graft promoted the in  vivo CD73 expression on host 
monocytes in a swine model of myocardial infarction. Our results suggest the upregu-
lation of ectonucleotidases on MSC-conditioned monocytes as an effective mechanism 
to amplify the long-lasting immunomodulatory and healing effects of MSCs delivery.
Keywords: cD73, adenosine, immunomodulation, mesenchymal stem cell, ectonucleotidase, myocardial 
infarction, purigernic signaling, regeneration
inTrODUcTiOn
Exacerbated immune responses hamper solid organ transplantation and regeneration of injured tis-
sues and lead to allergies, autoimmune diseases, and organ rejection. Antigen-presenting cells such 
as monocytes and dendritic cells (DCs) are responsible of linking the innate and adaptive phases 
of the immune response, providing signals to either trigger or downmodulate this response. Thus, 
Abbreviations: Ab, antibody; Ado, adenosine; 5′AMP, adenosine 5′-monophosphate; ATP, adenosine triphosphate; cATMSCs, 
adipose tissue-derived MSCs; CD39, nucleoside triphosphate diphosphohydrolase; CD73, ecto-5′-nucleotidase; DAMPs, 
damage-associated molecular patterns; DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride; DC, dendritic cell; HGF, 
hepatic growth factor; HLA-G, human leukocyte antigen-G; HO-1, heme oxygenase-1; IDO, indoleamine 2,3-dioxygenase; 
IL6, interleukin 6; MDDC, monocyte-derived dendritic cell; MI, myocardial infarction; MSC, mesenchymal stem cell; NO, 
nitric oxide; PGE2, prostaglandin E2; TGFβ, transforming growth factor-β; TNFα, tumor necrosis factor α; UCMSCs, umbilical 
cord MSCs.
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in some clinical settings, modulation of monocyte polarization 
and/or DC maturation is one of the key points to prevent an 
unwanted immune response.
The immune response can be specifically modulated by 
signals from the millieu, including cytokines, chemokines, and 
others such as purinergic mediators. Among them, adenosine 
triphosphate (ATP) promotes inflammation when it is found 
in high amounts during apoptosis and necrosis in damaged 
tissues (1–3); on the contrary, removal of extracellular ATP 
avoids exacerbated tissue inflammation. Extracellularly, ATP 
is sequentially hydrolyzed to ADP and 5′AMP by the ectoen-
zyme nucleoside triphosphate diphosphohydrolase (NTPD-1/
CD39) and to adenosine (Ado) by the ecto-5′-nucleotidase 
(ecto-5′-NT/CD73) (2, 4). The final product, Ado, is a powerful 
anti-inflammatory purine nucleoside, which has been described 
to immunosuppress macrophages, DCs, natural killer (NK), T, 
and B cells to promote tolerance (5, 6). Therefore, ATP hydroly-
sis is not only beneficial to reduce the pro-inflammatory ATP 
levels but also to produce the anti-inflammatory Ado. CD73 
expression has been linked to the regulatory phenotypes of T 
and NK cells (6–8), and it is also a cell marker for progenitor or 
mesenchymal stem cells (MSCs) (9).
Mesenchymal stem cells have been widely associated with both 
regenerative and immunomodulatory capabilities (10–12). For 
instance, MSCs derived from umbilical cord MSCs (UCMSCs) 
(i.e., Wharton’s jelly) powerfully inhibit the inflammatory 
response of stimulated T cells (12). Also, cardiac adipose tissue-
derived MSCs (cATMSCs), which represent a mesenchymal-like 
cell population with intrinsic cardiomyogenic potential (13), 
abrogate T  cell proliferation upon stimulation with allogeneic 
mature monocyte-derived DCs (14) and promote tissue repair 
and immune suppression in an in  vivo model of myocardial 
infarction (MI) (15, 16).
Among a broad number of mechanisms of action, MSCs gen-
erally modulate monocyte polarization toward an anti-inflam-
matory M2 phenotype (17–19) and restrain DC differentiation, 
resulting in the inhibition of the host immune response (20–22). 
At the same time, different in vivo models have demonstrated the 
need for monocytes/macrophages modulation to achieve healing 
and tissue repair by MSC treatment (19, 23, 24).
In this study, we first comparatively assess whether UCMSCs 
and cATMSCs (as distinct sources of MSCs) contribute to induce 
the functional expression of CD73 on monocytes, promoting the 
activation of their adenosinergic enzymatic activity. Finally, we 
evaluate the presence of infiltrated host monocytes expressing 
CD73 once cATMSCs are infused into swine post-infarcted 
myocardium.
MaTerials anD MeThODs
human caTMsc and UcMsc isolation and 
culture
The study protocols were approved by the Clinical Research 
Ethics Committee of our institution (Comitè Ètic d’Investigació 
Clínica, HuGTiP, Refs. CEIC: EO-10-13, EO-10-016 and 
EO-12-022), and conformed to the principles outlined in the 
Declaration of Helsinki. Written informed consent was obtained 
from donors.
Human cATMSCs were extracted from adipose tissue sur-
rounding the base of the heart and around the aortic root from 
patients undergoing cardiothoracic surgery prior to coronary 
artery bypass graft initiation (n = 6), as reported in Bayes-Genis 
et al. (13) and Perea-Gil et al. (14). In addition, fresh umbilical 
cords (UC, n = 6) were obtained after birth and UCMSCs were 
isolated and cultured as reported in Monguió-Tortajada et al. (12).
Monocyte isolation
Peripheral blood mononuclear cells were obtained from leukocyte 
residues from healthy donors from the Blood and Tissue Bank 
(Barcelona, Spain) (n = 22) by Ficoll Hypaque Pus™ density gra-
dient centrifugation (GE Healthcare Biosciences) at 1,800 rpm for 
30  min, and CD3+ cells were depleted using the RosetteSep™ 
Human CD3 Depletion Cocktail (StemCell Technologies). 
Monocytes were then isolated using the EasySep™ Human 
anti-CD14 Positive Selection Kit (StemCell Technologies) or 
the MagniSort Human CD14 Positive Selection kit (eBiosci-
ence) following manufacturers’ instructions. Recovered cells 
were counted using PerfectCount Microspheres (Cytognos) and 
assessed for purity (>90% CD14+) and viability [≥93% by FSC/
SSC and 7AAD− (BD) gating] in a Canto II flow cytometer (BD).
Monocyte Differentiation to Dcs
Monocytes were cultured at 1 × 106 cells/ml in complete medium 
composed of RMPI 1640 (Gibco) supplemented with 2  mM 
l-glutamine (Sigma), 100  U/ml penicillin (Cepa), 100  µg/ml 
streptomycin (Normon Laboratories), 5% human platelet lysate 
(Lonza), and DC differentiation cytokines: 300 IU/ml IL-4 and 
450 IU/ml GM-CSF (Miltenyi Biotech). After 6 days, monocyte-
derived dendritic cells (MDDCs) were harvested, counted, and 
assessed for viability and differentiation by 7AAD and CD11c 
staining, respectively (both from BD).
Monocyte and MDDc conditioning
Monocytes or MDDCs were cultured at 1 ×  106 cells/ml in a 
20:1 ratio over a layer of cATMSCs or UCMSCs, which were 
previously let adhere to the culture plates for 4 h. As a control, 
monocytes were cultured alone or in the presence of 500 ng/ml 
LPS (Sigma). Contact dependency was assessed using a 24-well 
transwell system with 0.4  μm-pore polycarbonate membrane 
(Costar). Monocytes (4 × 105) were seeded in each well and cAT-
MSCs or UCMSCs (2 × 104; 20:1 ratio) were applied to the upper 
chamber. Alternatively, monocytes were cultured in the presence 
of UCMSC conditioned media as published before (12).
After co-culture, monocytes or MDDCs were detached using 
accutase (Sigma) and washed with FACSFlow (BD) +  2% fetal 
bovine serum (FBS). Monocytes were stained with CD14-FITC 
and CD90-PE/Cy7 (BD) and separated by FACS in an Aria II 
sorter (BD). MDDCs were separated by FACS according to 
CD11c-Bv421+ (BD). Purity was always assured to be over 98%. 
Monocytes and MDDC were then pelleted and frozen at −80°C 
for whole RNA extraction.
Cell phenotype was assessed by incubation with CD11c-Bv421, 
CD14-FITC, CD25-PerCP/Cy5.5, CD39-Bv650, CD40-APC, 
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CD73-PE, CD90-PE/Cy7, CD163-Bv711, CD206-PE-CF594 
(BD), and/or CD80-PEVio770 (Miltenyi Biotech) or correspond-
ing isotype control antibodies and acquisition in FACSCanto II 
and LSR Fortessa flow cytometers (BD). Analysis was performed 
using FlowJo X software.
rna extraction and qPcr
Whole RNA content was isolated from cells using the RNeasy 
Mini kit (Qiagen). cDNA was synthesized using random hexam-
ers (Qiagen) and the iScriptTM One-Step RT–PCR Kit (BioRad 
Laboratories) according to the supplier’s protocol. Analysis of 
the monocyte polarization markers expression was performed as 
described previously (12), using the primer sequences indicated 
in Table S1 in Supplementary Material. Alternatively, 8  µl of 
cDNA was preamplified with the TaqManW PreAmp Master Mix 
Kit (Applied Biosystems) in a final volume of 50 µl. Subsequently, 
15 µl of preamplified cDNA were amplified in a final volume of 
50  µl containing 25  µl TaqMan 2× Universal PCR Master Mix 
and 2 µl of the following FAM-labeled primer/probes (Applied 
Biosystems): CD73 (Hs00169777_m1), CD90 (Hs00264235_s1), 
and 18S (Hs99999901_s1). Data from four independent experi-
ments were collected and analyzed on the LightCyclerW 480 
Real-Time PCR System (Roche); each sample was analyzed in 
duplicate. The difference in threshold cycle 2(−ΔΔCt) method 
was used to quantify the relative expression for each gene using 
18S as endogenous reference (25).
cytokine Determination
The human IL10 and tumor necrosis factor α (TNFα) levels were 
measured in supernatants of 72  h-cultured monocytes using 
commercial ELISA kits (U-Cytech) following the manufacturer’s 
instructions.
cD73 enzyme activity
Either MSCs or FACS-sorted conditioned monocytes were 
washed three times with MES buffer [0.025 M MES (Sigma) in 
0.9% NaCl (Braun) pH 6.0] and cultured at 50,000 cells/well in the 
presence or absence of 5′AMP (Sigma) and the CD39 inhibitor 
POM1 (Tocris) or CD73 inhibitor APCP (ADP analog; Sigma) 
when indicated. After 2  h at 37°C, cells were centrifuged and 
supernatants harvested to freshly quantify Pi concentration using 
the malachite green phosphate colorimetric assay kit (BioVision), 
following the manufacturer’s instructions. 5′AMP and APCP 
alone were confirmed to yield negative values, and Pi produc-
tion was calculated as the subtraction [Pi]cells+5′AMP − [Pi]cells alone. 
Alternatively, the 2 h-supernatant was snap frozen at −80°C and 
analyzed for Ado concentration using the Adenosine assay kit 
(BioVision), following the manufacturer’s instructions.
animal experimentation and 
immunostaining
All animal studies were approved by the local Animal 
Experimentation Unit Ethical Committee (no. ES 100370001499) 
and complied with all guidelines concerning the use of animals 
in research and teaching as defined by the Guide for the Care and 
Use of Laboratory Animals (NIH Publication No. 80-23, revised 
1996). Allogeneic porcine cATMSCs were isolated from cardiac 
adipose biopsy samples (average 0.4–5.9 g) from pigs undergoing 
cardiac surgery (n = 5), and processed as previously described 
(15). Succinctly, tissue specimens were washed in phosphate-
buffered saline to remove contaminating debris and red blood 
cells, and digested in 0.015% collagenase (Type II-B, Sigma-
Aldrich) for 30 min at 37°C in gentle agitation. The collagenase 
was inactivated by dilution with α-MEM containing 10% FBS, 
2 mM glutamine, 1% penicillin–streptomycin (Gibco Invitrogen 
Corp.) (α-MEM-FCS). The cell suspension was centrifuged for 
10 min at 1,200 × g, and the pellet was resuspended in α-MEM-
FCS and filtered through a 100-µm mesh. Adhered cells were 
finally grown to subconfluence in α-MEM supplemented with 
10% FBS, and cultured under standard conditions.
Engineered bioactive graft generation and implantation, MI 
induction, and immunohistological analysis was performed as 
described in previous studies (15, 16). In brief, a decellularized 
human pericardium-derived scaffold embedded with GFP-labeled 
porcine cATMSCs (treated animals; n = 7) or without cells (con-
trol animals; n = 7) was implanted covering the ischemic area in 
Landrace × Large White pigs 30 min after MI induction. In addi-
tion, a group submitted to the engineered bioactive graft enriched 
with cATMSCs but without MI induction was included (sham 
animals; n = 3). Animals were sacrificed after 30 days of follow-up.
Immunostaining was performed on cells grown in μ-dishes 
with glass bottom (Ibidi) or 10-µm myocardial sections 
against GFP, cardiac troponin I (Abcam), CD73, and CD163 
(Novus Biologicals) Abs (1:100). Subsequently, secondary 
Abs (1:500) conjugated to Alexa Fluor 488, Alexa Fluor 594, 
Alexa Fluor 647 (Molecular Probes), Cy2 and Cy3 (Jackson 
ImmunoResearch Laboratories) were applied. Samples were 
finally counterstained with Atto 488-conjugated phalloidin 
(1:40) and/or 4′,6-diamidino-2-phenylindole dihydrochloride 
(1:10,000) (Sigma), and analyzed under an Axio Observer 
Z1 confocal microscope (Zeiss). For CD163+ and CD73+ cell 
quantification, at least four different optical fields from each 
section were measured under Image-Pro Plus software (6.2.1 
version; Media Cybernetics, Inc.).
statistical analysis
Values are expressed as mean + or ± SD. Kolmogorov–Smirnov 
analysis was used to check for normality of data and appropri-
ate statistical tests are indicated for each dataset. Analyses were 
performed using the Graphpad Prism (6.0 version) and SPSS 
(21.0.0.0 version) softwares, and differences were considered 
significant when p < 0.05.
resUlTs
Monocyte Polarization by caTMscs and 
UcMscs
To investigate the effect of MSC conditioning, we first analyzed 
the capacity of different human MSCs to skew monocyte polari-
zation in vitro. Monocytes were co-cultured for 48 h with either 
cATMSCs or UCMSCs, and LPS as a positive control of monocyte 
activation. After co-culture, monocytes (CD14+/CD90mid) were 
easily isolated from MSCs (CD14dim/CD90high) by FACS accord-
ing to both their CD14 expression and lower expression of CD90 
FigUre 1 | cATMSCs and UCMSCs skew monocytes toward an “M2” phenotype. (a) Monocytes (CD14+/CD90mid) were separated by FACS after co-culture with 
cATMSCs or UCMSCs (CD14dim/CD90high). A representative gating analysis of monocytes co-cultured with UCMSCs (black dots) compared to UCMSCs alone (green 
dots) is shown. (B) Viability of co-cultured monocytes. Data are mean + SD of 11 independent experiments. (c) FACS-sorted monocytes were checked for the 
expression of M1 and M2 markers by qPCR after 48 h of co-culture. Data are expressed as mean + SD of the ratio between the M2 (ΣmRNA fold change of 
CD163, CD206, TGM2, and CCL18) and M1 marker (mRNA fold change of CD80) depicted in Figure S1 in Supplementary Material. Data accounts for three 
independent experiments. (D) Fold increase in CD80, CD163, and CD206 MFI of monocytes cultured for 72 h with cATDPCs or UCMSCs, relative to monocytes 
alone (−). Data accounts for three independent experiments. (e) IL10 and TNFα cytokine levels in 72 h-culture supernatants. Data are mean + SD of 12 independent 
experiments. Statistical differences are indicated where *p < 0.05 by one-way ANOVA with Tukey’s post hoc test compared to monocytes cultured alone (−).  
(F) Fold increase in IL10 mRNA of monocytes cultured for 48 h with cATDPCs or UCMSCs, relative to monocytes alone (−). Data accounts for four independent 
experiments. cATMSCs, cardiac adipose tissue-derived MSCs; UCMSCs, umbilical cord MSCs; TNFα, tumor necrosis factor α.
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compared to MSCs (Figure  1A). Monocytes exhibited better 
viability when co-cultured with MSCs (Figure 1B).
Both cATMSC and UCMSCs managed to upregulate the M2 
markers CD163, CD206, TGM2, and CCL18 in monocytes at the 
mRNA level (Figure S1 in Supplementary Material), while the M1 
marker CD80 remained unchanged. On the contrary, LPS activa-
tion of monocytes led to the increased expression of CD80. The 
relative mRNA expression of all markers studied (Figure  1C), 
suggested that both MSCs were promoting an M2 phenotype 
in monocytes. This phenotype was further assessed by surface 
protein expression, and while CD80 was unchanged, CD163 
and CD206 did increase when monocytes were co-cultured with 
MSCs (Figure  1D). Furthermore, the cytokine profile showed 
that MSCs promoted the secretion of IL10 by monocytes, while 
no TNFα was detected (Figure 1E). The increased IL10 mRNA 
transcription of sorted monocytes after co-culture with MSCs 
(Figure  1F) together with the undetectable IL10 in MSC’s 
supernatants (data not shown) could attribute IL10 production 
to monocytes, further confirming an anti-inflammatory profile 
induced by MSC co-culture.
induction of cD73 expression in 
Monocytes
After confirming the M2 skewing capabilities of cATMSCs and 
UCMSCs toward monocytes, we next studied the expression of 
adenosinergic ectoenzymes on these cells.
FigUre 2 | CD39 expression is maintained in monocytes co-cultured with MSCs. (a) Representative histograms depicting the CD39 expression of monocytes 
cultured for 72 h alone (−) or with LPS, cATMSCs, or UCMSCs. The isotype control is depicted in the top row; the % of positive cells and the MFI for the total 
monocyte population (CD14+/CD90mid) are indicated in each plot. (B) Percentage of CD39+ and (c) CD39 MFI of monocytes cultured for 72 h alone (−) or with LPS, 
cATMSCs or UCMSCs. Data account for 12 independent experiments. cATMSCs, cardiac adipose tissue-derived MSCs; UCMSCs, umbilical cord MSCs.
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CD39 was already present in fresh blood peripheral blood 
monocytes (data not shown) and remained highly expressed on 
monocytes cultured alone or in the presence of LPS, cATMSCs, 
or UCMSCs (Figure 2).
Interestingly, monocytes cultured on a layer of both types of 
MSCs expressed higher levels of CD73 protein at 24 and 48  h 
of culture compared to control (Figure 3A). CD73 mRNA was 
incremented more than 500 times in monocytes after 48  h of 
co-culture with either cATMSCs or UCMSCs in comparison to 
cultured alone (Figure 3B), pointing to the induction of protein 
expression. Of note, LPS activation of monocytes also incre-
mented CD73 expression. As a negative control, another classical 
MSC marker, CD90, was analyzed in conditioned monocytes. 
CD90 was found to be unchanged both at a protein and RNA lev-
els (Figures 3C,D), suggesting the apparent specificity to CD73 
acquisition and absence of a trogocytosis-like phenomenon.
As high levels of CD73 mRNA were detected after 48  h of 
conditioning, the CD73 protein expression and functional 
activity was further evaluated at 72 h of co-culture. Monocytes 
co-cultured with both cATMSCs and UCMSCs expressed higher 
levels of CD73 on the surface in comparison to control monocytes 
and LPS-stimulated monocytes (Figures 4A–C).
We also investigated whether direct cell contact between 
MSCs and monocytes was necessary to induce CD73 expression. 
For that purpose, co-culture experiments were performed using 
transwell culture plates, in which monocytes did not increase 
CD73 expression to the same extent compared to direct co-culture 
with MSCs (Figures  4B,C). To corroborate such observations, 
monocytes were cultured in the presence of MSC’s conditioned 
medium (Figure S2 in Supplementary Material), which neither 
induced CD73 expression in monocytes.
cD73 induced in conditioned Monocytes 
is Functional
The functionality of CD73 was then evaluated through the pro-
duction of inorganic phosphate (Pi) and Ado yielded from the 
hydrolysis of the CD73 substrate 5′AMP (Figure 4D). Confirming 
the high upregulation of CD73, MSC-co-cultured monocytes 
induced a much greater amount of Pi production compared 
to control and also LPS-stimulated monocytes (Figure  4E). Pi 
production was only detected when 5′AMP was added to the 
cells, as an indication of CD73 action rather than from other 
ectoenzymes. Enzyme activity inhibition was also evaluated by 
using the ADP analog APCP. These experiments showed a dose-
dependent abrogation of Pi production by MSC-conditioned 
monocytes and a fully blocked Pi production in LPS-stimulated 
monocytes (Figure 4E).
In parallel experiments, CD73 enzyme functionality was 
also confirmed in cATMSCs and UCMSCs as a positive control. 
As expected by their higher CD73 expression, both cATMSCs 
and UCMSCs displayed a higher 5′AMP hydrolytic activity 
which was dose-dependently blocked with APCP (Figure S3 in 
Supplementary Material).
To further discard the production of Pi from other upstream 
hydrolysis, we checked the Pi concentration in the presence of the 
CD39 inhibitor POM1 (Figure 4F). Again, Pi was only produced 
in the presence of the CD73 substrate 5′AMP, and while POM1 
FigUre 3 | CD73 is induced while CD90 remains unchanged in monocytes co-cultured with cATMSCs and UCMSCs. (a,c) Fold increase in CD73 and CD90 MFI 
of monocytes cultured for 24 or 48 h with LPS, ATDPCs, or UCMSCs (black dots), relative to 24 h-cultured monocytes alone (white dots). Statistical differences are 
indicated where *p < 0.05 and **p < 0.01 by two-way ANOVA compared to monocytes cultured alone. (B,D) Fold increase in CD73 and CD90 mRNA (ΔΔCt) of 
monocytes, relative to monocytes cultured alone. Statistical differences are indicated where *p < 0.05; **p < 0.01; and ***p < 0.001 by one-sample T test. Data are 
expressed as mean ± SD and accounts for four independent experiments of different monocyte and MSC donors. MSC, mesenchymal stem cell; cATMSCs, cardiac 
adipose tissue-derived MSCs; UCMSCs, umbilical cord MSCs.
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did not affect Pi production by MSC co-cultured monocytes, it 
was inhibited when APCP was added (Figure 4F).
We then confirmed the production of Ado by MSC co-
cultured monocytes, which was found in the supernatant only 
when 5′AMP was added to the monocytes and was abrogated 
by APCP addition (Figure  4G), indicating a CD73 functional 
enzymatic action.
MDDcs are not affected by Msc 
conditioning
In light of monocyte modulation by MSCs, we sought to explore 
the ability of MSCs to alter the maturation and CD73 expres-
sion of further differentiated cells such as MDDCs. Opposed to 
monocytes, the levels of CD73 and CD90 remained unchanged in 
MDDCs co-cultured with cATMSCs or UCMSCs (Figures 5A,B), 
which was confirmed as well by studying the mRNA levels of 
both CD markers (data not shown). On the other hand, MSCs 
failed to modulate MDDC maturation markers CD25 and CD40 
(Figures 5C,D), which were upregulated to the same extent by 
LPS stimulation, regardless of MSC co-culture.
host Monocytes acquire cD73 In Vivo in 
swine Post-infarcted Myocardium Treated 
with Porcine caTMscs
To investigate whether this in vitro effect occurred in vivo, we ana-
lyzed the presence of infiltrating monocytes and CD73 expression 
in a swine model of MI locally treated with porcine cATMSCs, 
previously reported by our group to reduce the amount of infil-
trating effector T cells in the infarcted tissue and to ameliorate 
the regeneration of the myocardium (15, 16). In these studies, 
treated animals vs. controls experimented a significant reduction 
in infarct size (3.4 ± 0.6 vs. 6.5 ± 1%; p = 0.015) and fibrosis in 
the infarct scar (collagen I/III ratio; 0.49 ± 0.06 vs. 1.66 ± 0.5; 
p =  0.019), and improved in cardiac function (left ventricular 
ejection fraction; 7.5 ± 4.9 vs. 1.4 ± 3.7%; p = 0.038, and stroke 
volume; 11.5 ± 5.9 vs. 3 ± 4.5 ml; p = 0.019).
Mesenchymal stem cells were delivered in the ischemic area 
by the implantation of an allogeneic engineered bioactive graft 
comprising GFP-labeled porcine cATMSCs, compared to the 
use of an “empty” graft in control animals. In this study, 1 month 
after the implantation, we detected how GFP+ cells (cATM-
SCs), expressing CD73 but not the monocyte marker CD163 
(Figures 6A,B), actively migrated from the graft to the infarcted 
tissue and persisted within the damaged area in treated animals. 
Noticeably, treated, control, and sham animals had infiltrating 
monocytes (CD163+) in the infarcted tissue (Figures 7A–C), but 
only in treated animals receiving cATMSCs after MI the infiltrat-
ing host monocytes gained CD73 expression. After quantification, 
no differences were found in the amount of CD163+ infiltrating 
monocytes between groups (Figure  7D). However, we could 
corroborate the gain on CD73 expression on host monocytes in 
treated vs. both control and sham animals in terms of absolute 
numbers (3.95 ±  2.45 vs. 1.12 ±  0.66 vs. 0.54 ±  0.83 CD73+ 
FigUre 4 | Monocytes co-cultured with cATMSCs or UCMSCs upregulate the adenosinergic enzymatic activity. Monocytes cultured for 72 h alone (−) or with LPS, 
cATMSCs or UCMSCs were checked for CD73 surface expression and activity. (a) Representative histograms of CD73 expression. The isotype control is depicted 
in the top row; the % of positive cells and the MFI for the total monocyte population (CD14+/CD90mid) are indicated in each plot. (B) Percentage of CD73+ and  
(c) CD73 MFI of monocytes as mean ± SD of 12 independent experiments. Tw: co-culture in transwell system. Statistical differences are indicated where *p < 0.05, 
**p < 0.01, and ***p < 0.001 by one-way ANOVA with Tukey’s post hoc analysis. (D) Schematic representation of the enzymatic hydrolysis of ATP/ADP to 5′AMP by 
CD39 and to Ado by CD73, which can be inhibited by POM1 and APCP, respectively. Inorganic phosphate (Pi) is produced as a byproduct in each step. (e) Levels 
of inorganic phosphate (Pi) produced by FACS-sorted monocytes analyzed after the addition of the CD73 substrate (5′AMP; 1 mM) with or without the CD73 
inhibitor (APCP). Data are presented in bars as the mean + SD concentration of Pi subtracted from the Pi present in monocytes without 5′AMP. Data account for 
9–13 independent experiments. (F,g) Levels of inorganic phosphate (Pi) (F) and of Ado (g) produced by FACS-sorted monocytes analyzed after the addition of the 
CD73 substrate (5′AMP; 1 mM) with or without the CD39 inhibitor (POM1) or the CD73 inhibitor (APCP). Data are presented in bars as the mean + SD 
concentration of Pi. Data accounts for four independent experiments. Statistical differences in each bar are compared to cells without 5′AMP or to the indicated 
groups where *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by two-way ANOVA with Tukey’s post hoc analysis. cATMSCs, cardiac adipose tissue-derived 
MSCs; UCMSCs, umbilical cord MSCs; ATP, adenosine triphosphate; Ado, adenosine.
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CD163+ cells; p = 0.028 and p = 0.019, respectively) (Figure 7E), 
and also in the percentage of CD73+ out of CD163+ monocytes 
(35 ± 11 vs. 8 ± 6 vs. 9 ± 12%; p = 0.001 and p = 0.0001, respec-
tively) (Figure 7F).
DiscUssiOn
In this work, we demonstrate the molecular interplay between 
MSCs and monocytes and highlight the induction of the 
adenosinergic pathway on monocytes as an additional mecha-
nism of immunomodulation and tissue healing. Particularly, we 
show that both human UCMSCs and human cATMSCs induce 
specifically in monocytes expression of the CD73 ectonucleoti-
dase. By this function, together with the constitutive expression of 
CD39, monocytes would gain the ability to sequentially hydrolyze 
ATP to increase extracellular Ado concentration. Moreover, we 
corroborate this effect in  vivo, as the local delivery of porcine 
cATMSCs into post-infarcted swine myocardium effectively 
FigUre 5 | CD73 and CD90 are not induced by MSC co-culture in MDDCs. (a,B) CD73 and CD90 MFI of MDDCs cultured for 48 h alone or with LPS, ATDPCs, or 
UCMSCs. (c,D) MFI values of the maturation markers CD25 and CD40 of MDDCs cultured for 48 h with or without cATMSCs or UCMSCs, and further stimulated 
with LPS (dashed bars) or not. Data are expressed as mean + SD and accounts for six independent experiments. MSC, mesenchymal stem cell; cATMSCs, cardiac 
adipose tissue-derived MSCs; UCMSCs, umbilical cord MSCs; MDDCs, monocyte-derived dendritic cells.
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resulted into the expression of CD73 on infiltrating host mono-
cytes, fostering an anti-inflammatory milieu.
The degradation of exogenous pro-inflammatory ATP into 
anti-inflammatory Ado has been attributed a key role for the con-
trol of inflammation in the local environment, and also to have 
systemic effects (5, 6, 26, 27). Ado reduces NK, macrophage, den-
dritic, B and T cells activation (4, 28–30), neutrophil accumula-
tion (31), while promotes the generation of M2 macrophages and 
expansion of regulatory T cells (CD39+/CD73+), thus establishing 
an adenosinergic amplification loop (5, 32–35). It further proves 
to be a powerful systemic immunosuppressant as Ado production 
is used as an immune evasion strategy by pathogens (36–38) and 
cancer cells (8, 39, 40), and its accumulation leads to a severe 
combined immunodeficiency in patients lacking ADA for Ado 
degradation (41, 42). Remarkably, Ado production also helps in 
wound healing and tissue repair (43), as inhibits post-hypoxic 
vascular leakage (44) and promotes angiogenesis via VEGF 
production by macrophages (45). These effects have been proven 
in vivo, where increased Ado levels reduced necrotic injury and 
edema formation, and limited infarct size in a mouse and swine 
models of MI (46, 47).
The presence of the purinergic ectoenzymes CD39/CD73 has 
been described for different organs and cell types. For instance, 
while MSCs and endothelial cells display a constitutive expression 
(48, 49), CD39/CD73 are triggered upon cell activation in the 
generation of Tregs, whereas CD73 is reduced in activated B cells 
(50). MSCs have also been shown to induce CD73 expression in 
NK cells, although to a much lesser extent than we observed in 
monocytes (7). In our experiments, we interestingly observed 
that LPS stimulation of TLR4 incremented CD73 expression in 
monocytes, probably as a balancing mechanism of cell activa-
tion, as was observed in mouse before (45, 51). However, only 
MSC co-culture lead to sustained CD73 expression and to active 
5′AMP hydrolysis by these cells, in a mechanism dependent of 
cell contact. Monocytes were polarized by both cATMSCs and 
UCMSCs toward an anti-inflammatory M2-like phenotype and 
to secrete immunomodulatory cytokines (IL10, CCL18) (17, 52, 
53), but it is worth to mention that other M2 switches such as 
the classical “M2A” induction by IL4 does not promote CD73 
upregulation (54).
These observations are important given the reported short 
lifespan of MSCs after infusion in vivo. Once injected i.v., MSCs 
get trapped in the lung barrier because of their big size and are 
removed by monocytes/macrophages within hours (55–58), 
thus theoretically impeding the action of MSCs in the target 
tissue. Nevertheless, MSCs still promote a long-lasting systemic 
immunosuppressive effect for the resolution of inflammation 
and regeneration of wounded tissue. These effects could be firstly 
mediated temporarily by paracrine mediators, but secondarily by 
the modulation of the host’s immune cells. In this sense, soluble 
molecules such as interleukin 6, prostaglandin E2, transforming 
growth factor-β, indoleamine 2,3-dioxygenase, hepatic growth 
factor, human leukocyte antigen-G, TSG6, and extracellular 
vesicles have been attributed to promote such paracrine effects 
(12, 58, 59). Moreover, given that MSCs express CD39 and CD73 
constitutively, Ado production is also part of MSC’s paracrine 
FigUre 6 | Allogeneic cATMSCs migrated to the infarcted myocardium after graft implantation in swine. Representative confocal microscope images showing  
(a) porcine cATMSCs in in vitro culture or (B) sections within the infarcted myocardium. (a) Porcine cATMSCs are positive for CD73 (left, red) and negative for 
CD163 (right, red). (B) Presence of GFP+ porcine cATMSCs (empty arrows) in post-infarcted myocardium, also positive for CD73 but negative for CD163 (lower 
panels). Cell morphology, cardiac muscle, and cell nuclei are also counterstained using Atto 488-phalloidin, anti-cTnI Ab, and DAPI, respectively. Scale 
bars = 50 µm. cATMSCs, cardiac adipose tissue-derived MSCs; DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride.
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immunosuppressive activity. In fact, CD73 itself can also have 
systemic effects as it can be both shed from the membrane and act 
in its soluble form (60–62) and also be released within extracel-
lular vesicles, as proved by Amarnath et al. in an animal model of 
Th1 inflammation treated with infused MSCs, in which systemic 
Ado production by released CD73 mediated the resolution of 
inflammation (63).
Following these MSC paracrine primary immunomodulatory 
effects, MSCs may modulate the action of immune cells for the 
generation of regulatory environments. Monocytes, which are 
FigUre 7 | CD73 is also induced in vivo in host monocytes in swine post-infarcted myocardium treated with porcine cATMSCs. (a–c) Infiltrating CD163+ 
monocytes (white arrows), some of them expressing CD73 (red arrows) in a cATMSC-treated animal (a), and CD163+ monocytes (white arrows) in a control (B) and 
sham (c) animals, both negative for CD73. CD73 is shown in red and CD163 in white, and nuclei are counterstained with DAPI in blue. Scale bars = 50 µm.  
(D,e) Histograms showing the number of CD163+ monocytes (D), CD73+ CD163+ monocytes (e) per optical field in all studied groups. (F) Percentage of CD73+ 
monocytes out of the CD163+ monocytes. Differences in immunohistochemical quantifications were compared using one-way ANOVA for multiple comparisons, 
with Tukey’s test for the post hoc analysis. cATMSCs, cardiac adipose tissue-derived MSCs; DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride.
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present in great numbers especially in the lungs, would interact 
with the infused MSCs and acquire an M2-like phenotype, 
including CD73 mRNA expression in less than 24 h, as shown 
by our results. These CD39+/CD73+ monocytes are fit to easily 
go through the lung barrier and migrate to the inflamed tissue 
to promote in situ immunomolulation and healing. Although the 
level of CD73 activity was much higher in MSCs, CD39+/CD73+ 
monocytes would have the advantage of migration and delivering 
a targeted local effect.
At the same time, when MSCs are delivered directly to the 
injured tissue, they can regulate monocyte function locally, 
which are, together with granulocytes, the first cells to infil-
trate into inflamed tissue (64). Remarkably, we previously 
demonstrated the use of a scaffold of decellularized human 
pericardium for the local delivery of porcine cATMSCs to 
the post-MI injured tissue. MSC treatment attained in  vivo 
attenuation of inflammation (i.e., fewer activated T cells) and 
promoted the regeneration of the damaged myocardial tissue in 
post-infarcted pigs (16). Here, we also show the acquisition of 
CD73 expression by infiltrated host monocytes in MSC-treated 
animals, thus establishing an adenosinergic positive loop. The 
gain in CD73 by host monocytes was dependent on the combi-
nation of monocyte activation in response to pro-inflammatory 
damage-associated molecular patterns released after MI and 
the modulation by cATMSCs contained within the graft, given 
that both control and sham animals lacked presence of CD73 
in monocytes.
This finding agrees with those reported by others confirming 
that collaboration with monocytes has been found to be essential 
for MSCs activity, from immunomodulation and Treg generation 
(17, 65) to stopping infiltration and aiding in the regeneration of 
inflamed tissue (19, 23, 24, 66).
Noteworthy, since the in  vitro co-culture setting and the 
in  vivo local administration of MSCs hinders the distinction 
between monocyte- and MSC-derived soluble CD73, we did not 
check for presence of soluble CD73, which is a limitation of our 
study. This might be underestimating the upregulation in CD73 
protein expression by monocytes and thus could explain in part 
the differences between the mRNA and protein fold increase 
found in monocytes.
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Our functional experiments were focused to check the func-
tionality of CD73 upregulation on MSC-conditioned monocytes. 
Therefore, we studied the last enzymatic step of extracellular Ado 
production mediated by the ectonucleotidase CD73. Pi and Ado 
levels did not increase in the absence of 5′AMP, and their produc-
tion was only affected by APCP while not by POM1. Thus, Pi and 
Ado production could be attributed to CD73-mediated 5′AMP 
hydrolysis and discarded the action of other ectoenzymes such 
as CD39 or Pi release due to FACS-related sheer stress, as all cells 
underwent the same FACS separation.
We exclusively analyzed the presence of the ectoenzymes 
mediating the canonical pathway of Ado production, given 
that ATP would be incremented and readily available in sites of 
injury and inflammation such as a post-MI tissue. Nevertheless, 
other enzymatic pathways leading to the extracellular avail-
ability of 5′AMP, such as the conversion of NAD+ by CD38/
CD203a (67) may be also playing a part in MSC-conditioned 
monocytes.
Finally, studies on the modulation by MSC of further differ-
entiated cells such as DCs have been proven controversial. Most 
studies describe MSCs able to modulate DC biology specially 
when added early in the differentiation process. However, in line 
with our observations, some authors report no effect of MSCs on 
later steps of differentiation or maturation process (20, 21). This 
seems to indicate that the MSC modulation would preferentially 
act on non-activated cells.
In summary, the upregulation of CD73 in MSC-conditioned 
monocytes emerges as an additional potential mechanism 
supporting the long-lasting immunomodulatory and healing 
effects of MSCs delivery. A better understanding of the signal-
ing pathways triggered in monocytes by MSCs will help to 
better define new therapies for tissue injury and regenerative 
medicine.
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